{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["datopotamab deruxtecan"]],"indication":"TROP2-positive advanced/metastatic non-squamous NSCLC without actionable genomic alterations","name":"TROPION-Lung17","nct_id":"NCT07291037","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-lung17-nct07291037. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TROPION-Lung17","arms":[{"description":"Participants in the Dato-DXd monotherapy group will receive Dato-DXd as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.","label":"Arm A: Datopotamab deruxtecan (Dato-DXd) monotherapy","type":"EXPERIMENTAL"},{"description":"Participants in the docetaxel monotherapy group will receive docetaxel as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.","label":"Arm B: Docetaxel monotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2029-01-29","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Datopotamab deruxtecan (Dato-DXd)","otherNames":["DS-1062a"],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-10","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-01-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"Approximately 2.5 years"},{"measure":"Overall survival (OS)","timeFrame":"Approximately 3.5 years"}],"references":[],"start_date":{"date":"2025-10-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations","url":"https://clinicaltrials.gov/study/NCT07291037"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-lung17-nct07291037"}